Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Sun

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Contemporary Clinical Trials|July 14, 2023
Framing the statistical criteria for accelerated approval of oncology drugs: A pathway for front runnersCong Chen, Linda Sun
Contemporary Clinical Trials|April 17, 2023
Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpointHeng Zhou, Linda Sun, Meihua Wang
Contemporary Clinical Trials Communications|November 30, 2023
A promising biomarker adaptive Phase 2/3 design - Explained and expandedCong Chen, Linda Sun, Xuekui Zhang
Journal of Biopharmaceutical Statistics|February 27, 2013
Evaluation of early efficacy endpoints for proof-of-concept trialsCong Chen, Linda Sun, Chih-Lin Li
Contemporary Clinical Trials|July 8, 2022
Family-wise type I error rate control for an extended 2-in-1 design with graphical approach in oncology drug developmentWen Li, Heng Zhou, Calvin Jia, et al.
Pharmaceutical Statistics|June 12, 2020
Bayesian optimal phase II clinical trial design with time-to-event endpointHeng Zhou, Cong Chen, Linda Sun, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 1, 2019
Erectile dysfunction in patients with haemophiliaMing Yang, Haowei Linda Sun, Shannon C Jackson
Contemporary Clinical Trials|April 16, 2021
A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicitiesHeng Zhou, Cong Chen, Linda Sun, et al.
Research and Practice in Thrombosis and Haemostasis|October 11, 2024
Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort studyJaclyn Shelton, Michelle Millions, Roy Khalife, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 8, 2017
Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice AuditHaowei Linda Sun, Stella Chan, Paul Yenson, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Contemporary Clinical Trials|July 14, 2023
Framing the statistical criteria for accelerated approval of oncology drugs: A pathway for front runnersCong Chen, Linda Sun
Contemporary Clinical Trials|April 17, 2023
Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpointHeng Zhou, Linda Sun, Meihua Wang
Contemporary Clinical Trials Communications|November 30, 2023
A promising biomarker adaptive Phase 2/3 design - Explained and expandedCong Chen, Linda Sun, Xuekui Zhang
Journal of Biopharmaceutical Statistics|February 27, 2013
Evaluation of early efficacy endpoints for proof-of-concept trialsCong Chen, Linda Sun, Chih-Lin Li
Contemporary Clinical Trials|July 8, 2022
Family-wise type I error rate control for an extended 2-in-1 design with graphical approach in oncology drug developmentWen Li, Heng Zhou, Calvin Jia, et al.
Pharmaceutical Statistics|June 12, 2020
Bayesian optimal phase II clinical trial design with time-to-event endpointHeng Zhou, Cong Chen, Linda Sun, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 1, 2019
Erectile dysfunction in patients with haemophiliaMing Yang, Haowei Linda Sun, Shannon C Jackson
Contemporary Clinical Trials|April 16, 2021
A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicitiesHeng Zhou, Cong Chen, Linda Sun, et al.
Research and Practice in Thrombosis and Haemostasis|October 11, 2024
Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort studyJaclyn Shelton, Michelle Millions, Roy Khalife, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 8, 2017
Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice AuditHaowei Linda Sun, Stella Chan, Paul Yenson, et al.
Pageof 6